



© 2008 BizInt Solutions, Inc.
www.bizcharts.com





© 2008 BizInt Solutions, Inc.
www.bizcharts.com

Case study: HER2 inhibitors
Search strategies

- Searches done in April and June 2008
- PP: pharmacological activity = ErbB-2 tyrosine kinase inhibitor (KI-TYE2-AN)
- RDF: text contains "HER2"
- RDI: mechanism of action = HER2 inhibitors
- TPharma/IDdb: Action = Erbb2 tyrosine kinase receptor inhibitor
- Integrity: Action = HER2(erbB2) inhibitors

BizInt Smart Charts 2008

Case study: HER2
Search results

Records retrieved	*April 08*	*June 08*
Pharmaprojects	77	77
R&D Focus	76	80
R&D Insight	35	39
Thomson Pharma	60	62
Prous Integrity	130	136

BizInt Smart Charts 2008

© 2008 BizInt Solutions, Inc.
www.bizcharts.com

Case study: HER2

Identifying unique compounds

	Drug	Synonyms	Common Drug Name	Database
126	MAb, HER2/neu, InNexus	DXL 702	DXL 702	IMS R&D Focus
127	DXL-702		DXL 702	PJB Pharmaprojects
128	DXL-702		DXL 702	Prous Integrity Compounds
129	Research programme: anti-HER2 monoclonal antibodies - InNexus Biotechnology	DXL 702 DXL702	DXL 702	Adis R&D Insight

"Generate Common Drug Names" tool automatically matches product names and synonyms

BizInt Smart Charts 2008

Case study: HER2 (June 08)

273 unique compounds in 394 records



% of unique compounds retrieved from each database

BizInt Smart Charts 2008

© 2008 BizInt Solutions, Inc.
www.bizcharts.com

Case study: HER2

Coverage by development phase



BizInt Smart Charts 2008

Case study: HER2 inhibitors

Search strategies

- Also searched the HER2 target tree (primary target = HER2 or HER2/NEU) in PP

PJB Pharmaprojects: pjb_her2_mech_jun08

	Product	Pharmacological Activity	Target Names	Search Strategy
1	PX-104.1	ErbB-2 tyrosine kinase inhibitor (KI-TYE2-AN) Immunostimulant (IM-AG)	v-erb-b2 erythroblastic leukaemia viral oncogene homologue 2, neuro/glioblastoma	Mechanism
2	anti-ErbB-2 MAbs, Enzon	ErbB-2 tyros (KI-TYE2-AN		
	PKI-166	ErbB-2 tyros (KI-TYE2-AN ErbB-1 tyros (KI-TYE1-AN		

PJB Pharmaprojects: pjb_her2_jun08 target search

	Product	Pharmacological Activity	Target Names	Search Strategy
1	2B-1	CD16 antagonist (CD-16-AN)	v-erb-b2 erythroblastic leukaemia viral oncogene homologue 2, neuro/glioblastoma derived oncogene homologue (avian) Fc fragment of IgG, low affinity IIIa, receptor (CD16) Fc fragment of IgG, low affinity IIIb, receptor (CD16b)	Target
2	ABY-002	Not applicable (NA)	v-erb-b2 erythroblastic leukaemia viral oncogene homologue 2, neuro/glioblastoma derived oncogene homologue (avian)	Target
3	AE-37	ErbB-2 tyrosine kinase inhibitor (KI-TYE2-AN) T helper cell stimulant (LYM-TH-AG)	v-erb-b2 erythroblastic leukaemia viral oncogene homologue 2, neuro/glioblastoma derived oncogene homologue (avian)	Target

© 2008 BizInt Solutions, Inc.
www.bizcharts.com

Case study: HER2 inhibitors

Search strategies - Pharmaprojects

- Used the compare user comments feature to evaluate compounds retrieved by target vs. pharmacological activity/mechanism

Pharmacological Activity	Target Names	Search Strategy
Immunostimulant (IM-AG)	v-erb-b2 erythroblastic leukaemia viral oncogene homologue 2, neuro/glioblastoma derived oncogene homologue (avian)	Target
ErbB-2 tyrosine kinase inhibitor (KI-TYE2-AN) ErbB-1 tyrosine kinase inhibitor (KI-TYE1-AN) Endothelial growth factor receptor kinase inhibitor (KI-GFEN-AN)	v-erb-b2 erythroblastic leukaemia viral oncogene homologue 2, neuro/glioblastoma derived oncogene homologue (avian) epidermal growth factor receptor (erythroblastic leukaemia viral (v-erb-b)	Mechanism /Also:/ Target

Case study: HER2 inhibitors

Search strategies - Pharmaprojects



© 2008 BizInt Solutions, Inc.
www.bizcharts.com

Case study: HER2 inhibitors

Search strategies - Pharmaprojects

PJB Pharmaprojects: PP - HER2 searched by mech and target

	Product	Pharmacological Activity	Target Names	Search Strategy
83	**INSM-18**	Insulin like growth factor 1 antagonist (GF-IN-1-AN) ErbB-2 tyrosine kinase inhibitor (KI-TYE2-AN) IGF-1 receptor tyrosine kinase inhibitor (KI-GFIN1-AN)	insulin-like growth factor 1 receptor v-erb-b2 erythroblastic leukaemia viral oncogene homologue 2, neuro/glioblastoma derived oncogene homologue (avian)	Mechanism
84	**anticancer MAbs, Xencor-2**	CD20 antagonist (CD-20-AN) ErbB-2 tyrosine kinase inhibitor (KI-TYE2-AN)	membrane-spanning 4-domains, subfamily A, member 1 v-erb-b2 erythroblastic leukaemia viral oncogene homologue 2, neuro/glioblastoma derived oncogene homologue (avian)	Mechanism
85	**T-3100**	Oncogene inhibitor (ONCOG-AN) ErbB-2 tyrosine kinase inhibitor (KI-TYE2-AN) Myc inhibitor (MYC-AN)	v-myc myelocytomatosis viral oncogene homologue (avian) v-erb-b2 erythroblastic leukaemia viral oncogene homologue 3 (avian)	Mechanism

Why were these compounds not retrieved by the target search?

BizInt Smart Charts 2008

Case study: HER-2

RDI – “missing records”

- Strategy: mechanism of action = HER2 inhibitors
- AE-37: mech = immunostimulants
- BMS 690514: mech = Epidermal growth factor receptor antagonists, Protein-tyrosine kinase receptor antagonists
- CAB 051: mech = Epidermal growth factor receptor antagonists
- E 75: mech = T cell stimulants
- HER-2 Protein AutoVac: mech = Epidermal growth factor inhibitors, Immunostimulants
- JNJ-26483327: mech = Epidermal growth factor receptor antagonists, Protein tyrosine kinase inhibitors

BizInt Smart Charts 2008

© 2008 BizInt Solutions, Inc.
www.bizcharts.com

Case study: HER-2
Conclusions on coverage variation

- Different compounds are retrieved from each database because of differences in indexing.
- A search of any single database will retrieve only 20-40% of the unique compounds.
- Searches will need to be revised to identify "missing" records, especially for topics like HER-2.

BizInt Smart Charts 2008

Case study: HER2
Updated and Added Records

Number of Updated Records (Apr08 - Jun 08)



BizInt Smart Charts 2008

© 2008 BizInt Solutions, Inc.
www.bizcharts.com

Case study: HER-2

Coverage Variation – "Reference Rows"



Case study: TAP

Coverage Variation – "Reference Rows"



© 2008 BizInt Solutions, Inc.
www.bizcharts.com

Surfing the Pipeline

Keep in mind…

- Drug pipeline records are not abstracted from a reference document (as with patents)
- Each record is an **editorial view** of the compound based on a range of sources.
- Each publisher has a unique background and focus.
- 10-20 editors at each publisher are maintaining several thousand active compounds.

BizInt Smart Charts 2008

BIZINT SOLUTIONS

If you'd like to discuss these results in more detail, visit us in **Booth 1400** in the exhibit hall.

Slides available at:
www.bizcharts.com ("Smart Talk")
Or email "diane @ bizcharts.com"

BizInt Smart Charts 2008

© 2008 BizInt Solutions, Inc.
www.bizcharts.com